Therapeutic drug monitoring in peritoneal dialysis: A case of nontuberculous mycobacterium catheter-related infection treated with amikacin.

Sanae KojyaHideo ShiohiraYoshitsugu SunagawaShoji TsuneyoshiKentaro KohaguraYusuke OhyaFusako YonahaNobuo HokamaKatsunori Nakamura

Published in: Clinical case reports (2020)

The pharmacokinetics of amikacin makes it difficult to predict the appropriate dosing to avoid harmful side effects in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). The implementation of therapeutic drug monitoring may be useful in controlling amikacin serum concentrations in patients receiving CAPD.

Keyphrases

peritoneal dialysis
end stage renal disease
patients undergoing
blood pressure
primary care
healthcare
mycobacterium tuberculosis
chronic kidney disease
quality improvement
drug induced